Arachidonoyl ethanolamide phosphate, an endocannabinoid, is an endogenous ligand for cannabinoid receptors in the central nervous system (CB1 subtype) and peripheral immune cells (CB2 subtype).

Arachidonoyl ethanolamide phosphate (AEA; 1 μM) is shown to induce apoptotic bodies formation and DNA fragmentation, hallmarks of programmed cell death, in human neuroblastoma CHP100 and lymphoma U937 cells[1]. An anti-proliferative action of Arachidonoyl ethanolamide phosphate in human breast carcinoma cells, due to a CB1-like receptor-mediated inhibition of the action of endogenous prolactin at its receptor. Arachidonoyl ethanolamide phosphate has an activation of cell proliferation in hematopoietic cell lines. Arachidonoyl ethanolamide phosphate is a neuromodulator that mediate a retrograde signaling pathway to modulate neurotransmitter release at the presynaptic terminal[1]. Arachidonoyl ethanolamide phosphate (0.1-10 μM; for 5 days) time- and concentration-dependently inhibits rat C6 glioma cell proliferation[2].

183323-26-4

C22H38NO5P

427.522

Arachidonoyl ethanolamide phosphate

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years